Xanthine oxidoreductase-IN-6

Xanthine oxidoreductase-IN-6 (Compound 4) is an orally active xanthine oxidoreductase (XOR) inhibitor with an IC50 of 170 nM. Xanthine oxidoreductase-IN-6 can block the final step of uric acid biosynthesis and lower serum uric acid levels. Xanthine oxidoreductase-IN-6 also shows Cytochrome P450 3A4 (CYP3A4) inhibitory activity. Xanthine oxidoreductase-IN-6 can be used for the research of hyperuricemia[1].

Product Specifications

CAS Number

[4329-78-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Cytochrome P450; Xanthine Oxidase

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Metabolic Disease

Purity

99.33

Smiles

C1(C2=CC=NC=C2)=NNC(C3=CC=NC=C3)=N1

Molecular Formula

C12H9N5

Molecular Weight

223.24

Precautions

H302, H315, H319, H335

References & Citations

[1]Sato T, et al. Discovery of 3- (2-cyano-4-pyridyl) -5- (4-pyridyl) -1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected]. Bioorg Med Chem Lett. 2009 Nov 1;19 (21) :6225-9.